Phase II, Single Arm, Open Label, Study of the Combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-Cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Tazemetostat (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Primary cutaneous anaplastic large cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 15 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2024 Status changed from not yet recruiting to recruiting.
- 20 Sep 2024 Planned End Date changed from 24 Apr 2028 to 24 Nov 2028.